C. diff - Tru-D SmartUVC Tru-D SmartUVC

Tru-D is on a Mission to Eradicate C. diff and other Hospital-acquired Infections

Tru-D SmartUVC uses chemical-free, environmentally-friendly UVC energy to kill C. diff and other deadly pathogens. UVC light has been proven to reduce the spread of C. diff in hospitals and health care facilities, saving patients’ lives and hospitals’ dollars. Validated by more than a dozen independent studies as well as the only randomized clinical trial on UV disinfection, Tru-D is on a mission to eradicate C. diff and other hospital-acquired infections that adversely affect patient outcomes.

C. diff Statistics

453,000 cases per year
29,300 associated deaths
$15,275 average cost to a hospital

C. diff Statistics

C. diff is one of the most deadly and heard-to-kill superbugs that is most commonly found in health care facilities. While it can be resistant to antibiotics, it cannot withstand UV energy.

CLICK HERE TO LEARN MORE

Does Tru-D Kill C. diff?

12% C. diff Reduction at Chesapeake Regional
11% C. diff Reduction in BETR-D study
HAIs eliminated at Yavapai Regional

CLICK HERE TO LEARN MORE

BETR-D Randomized Clinical Trial

11% Hospital-wide C. diff Reduction

BETR-D Randomized Clinical Trial

When the BETR-D study analysis is expanded to all patients who entered the hospital, researchers saw a statistically significant 11% reduction in C. diff rates hospital-wide.

CLICK HERE TO LEARN MORE

C. Diff Foundation

Tru-D Proudly Supports the C. Diff Foundation

C. Diff Foundation

The C. Diff Foundation is dedicated to supporting public health through education and advocating for C. diff prevention, treatment, environmental safety and support worldwide.

Tru-D is a proud sponsor of the C. Diff Foundation. Visit cdifffoundation.org to learn more about their organization and how it impacts C. diff patients.

LEARN ABOUT THE C. DIFF FOUNDATION

Since conducting a month-long study in 2016, Yavapai Regional Medical Center has not had a single, reported hospital-acquired infection in the hospital wing used in the trial.

Click here to read how Tru-D helped eliminate C. diff infections at Yavapai.
“We determined that by creating a solid baseline of cleanliness and reducing as much bioburden as possible throughout the unit, we were able to reduce transmissions. In fact, Yavapai has not had a transmission reported since December 8, 2016.”

– Kim Horn, Yavapai Regional Medical Center
During the BETR-D study, Chesapeake Regional Healthcare saw a 12% C. diff reduction. Click here to learn more.
“We did experience a significant decrease in both infection and colonization rates with all multi drug resistant organisms (MDROs) and about a 12% decrease in C. diff infections during the arms of the study that included Tru-D units and bleach.”

—Tiffany Silmon, Chesapeake Regional Healthcare

Tru-D is on a Mission to Eradicate C. diff and other Hospital-acquired Infections

C. diff Statistics

C. diff Statistics

Does Tru-D Kill C. diff?

BETR-D Randomized Clinical Trial

BETR-D Randomized Clinical Trial

C. Diff Foundation

C. Diff Foundation

Since conducting a month-long study in 2016, Yavapai Regional Medical Center has not had a single, reported hospital-acquired infection in the hospital wing used in the trial.

Click here to read how Tru-D helped eliminate C. diff infections at Yavapai.

“We determined that by creating a solid baseline of cleanliness and reducing as much bioburden as possible throughout the unit, we were able to reduce transmissions. In fact, Yavapai has not had a transmission reported since December 8, 2016.”

During the BETR-D study, Chesapeake Regional Healthcare saw a 12% C. diff reduction. Click here to learn more.

“We did experience a significant decrease in both infection and colonization rates with all multi drug resistant organisms (MDROs) and about a 12% decrease in C. diff infections during the arms of the study that included Tru-D units and bleach.”